EMA committee recommends approvals for Lilly's weight loss drug, Mirati's KRAS inhibitor and more
The European Medicines Agency’s human medicines committee (CHMP) this week gave a thumbs-up to nine label expansions and eight new drugs, including Eli Lilly’s tirzepatide …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
